Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study suggests that immune privilege guardians and the pro-inflammatory cytokine interferon-γ significantly influence the dynamics of alopecia areata, supporting the hypothesis that immune privilege collapse is crucial in its development.

This report presents a case where multiple steatocystomas appeared in a psoriatic patient during ustekinumab treatment, suggesting the drug may unmask a genetic predisposition to steatocystoma multiplex.

This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.

This study reports that a novel gain-of-function mutation in TMEM173, combined with polymorphisms in TMEM173 and IFIH1, results in a distinct clinical phenotype with features of SAVI, including alopecia and photosensitivity.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

In this study, researchers demonstrated that CD4 T cells from skin-draining lymph nodes in mice with alopecia areata can transfer the disease to recipient mice, revealing a critical role for CD4 T cells in disease development and suggesting potential therapeutic targets.

This study observed distinct plasma miRNA profiles in alopecia areata, identifying several miRNAs downregulated in both mild and severe forms; machine learning models demonstrated strong predictive accuracy, and kinase inhibitors were suggested as promising therapeutic targets based on pathway analysis.

Discoid lupus erythematosus involves immune activation and fibrosis around hair follicles, with shared pathways across humans, dogs, and mice, suggesting potential treatments for both humans and animals.

In this study, researchers found that CD4 T cells from the skin draining lymph nodes of mice with alopecia areata can transfer the disease to recipient mice, highlighting the key role of these cells and their interaction with CD8 T cells in the disease's development.

This review outlines the proposed theories behind the development of alopecia areata, emphasizing the autoimmune process involving lost immune privilege in hair follicles, and stresses the need to pinpoint specific pathogenic mechanisms for potential treatments.

This study reported that CCT oligodeoxynucleotide induced patchy hair loss in male mice with specific genetic traits, suggesting gender and genetic preferences in immune response.

The authors concluded that increasing regulatory T cells in patients with alopecia areata may improve hair follicle regeneration by reducing autoimmune responses, suggesting a potential new therapeutic approach since current treatments are often ineffective with high relapse rates.

In this study, researchers found that changes in immune cell infiltration and immune-related gene expression may contribute to the immune microenvironment changes in male androgenetic alopecia.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.

This review discusses the roles of interferon-γ and PPAR-γ-mediated signalling in scarring alopecia, suggesting these pathways as potential therapeutic targets, but it reports no new empirical results.

In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.

This study established a new mouse model for TCE-induced skin sensitization and reported that proinflammatory cytokines TNF-α, IFN-γ, and IL-2 significantly contribute to this sensitization process.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

In this study, researchers found that Hashimoto's thyroiditis patients, despite being in euthyroid status, experienced more severe extrathyroidal symptoms compared to healthy controls, and elevated thyroid antibodies were linked to lower health-related quality of life and increased inflammation.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study suggests that SOCS3 treatment may effectively inhibit alopecia areata by suppressing CD8+ T cell activity and IFN-γ production.

This study found that patients with active severe alopecia areata exhibited decreased CD200 expression on T and B lymphocytes, which may be linked to an imbalance in Th1/Th2 immune equilibrium.

This study found that mycophenolate may stabilize β-catenin and counteract interferon-γ-induced catagen changes in human dermal papilla cells, which could promote hair growth.

This study reports that hair follicle-derived mesenchymal stem cells significantly reduced hair loss and inflammation in alopecia areata models, suggesting a potential therapeutic approach.

This study found that topical application of Astragalus membranaceus extract induced hair regrowth and reduced immune response markers in mice with natural hair loss.

Sorafenib may cause hair loss in a way similar to alopecia areata.

This study discusses the epithelial-immune microenvironment in chronic skin diseases, such as psoriasis and atopic dermatitis, and highlights current and future treatment strategies targeting inflammatory loops within these diseases.

In this study, patients with alopecia areata showed significantly elevated serum levels of IFN-γ and severely deficient vitamin D3 levels compared to healthy controls.